Saroglitazar

Saroglitazar, the magnesium salt of (2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrrol-1-yl}ethoxy)phenyl]propanoic acid, is a first-in-class dual agonist of peroxisome proliferator-activated receptors alpha and gamma (PPARalpha/gamma) with predominant PPARalpha and moderate PPARgamma activity. Developed by Zydus Cadila (now Zydus Lifesciences) under the development code ZYH1, it was the first new chemical entity discovered entirely in India to receive marketing authorization, granted in 2013 by the Drug Controller General of India for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with type 2 diabetes mellitus not controlled by statins alone. In 2020, saroglitazar received a second indication in India for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH), making it the first drug approved anywhere in the world for that condition. The compound is marketed in India as Lipaglyn at an oral dose of 4 mg once daily and has subsequently received approval in Mexico.

The dual PPARalpha/gamma mechanism provides a pharmacological profile that bridges the lipid-lowering activity of fibrates (PPARalpha agonists) with the insulin-sensitizing activity of thiazolidinediones (PPARgamma agonists) while avoiding the weight gain, edema, and cardiovascular risk signals that led to the withdrawal of earlier glitazar-class compounds (muraglitazar, tesaglitazar, ragaglitazar). PPARalpha activation increases hepatic fatty acid beta-oxidation, reduces triglyceride synthesis, and elevates high-density lipoprotein cholesterol. PPARgamma activation enhances peripheral insulin sensitivity in adipose and skeletal muscle tissue, reduces hepatic gluconeogenesis, and modulates adipokine secretion. The dual activation also provides anti-inflammatory and antifibrotic effects in the liver through suppression of nuclear factor kappa B signaling, reduction of pro-inflammatory cytokines (tumor necrosis factor alpha, interleukin-6, interleukin-1 beta), and modulation of the leptin-to-adiponectin ratio.

Pharmacokinetics in healthy human subjects are characterized by rapid oral absorption (median time to peak plasma concentration of 0.6 to 1.0 hours under fasting conditions), extensive plasma protein binding (approximately 96 percent), hepatic metabolism to saroglitazar sulfoxide and other metabolites, and a terminal elimination half-life of approximately 3 to 6 hours depending on sex and formulation. The compound does not accumulate on repeated once-daily dosing, and food does not meaningfully affect overall systemic exposure. The pharmacokinetic profile has been characterized in healthy volunteers, in patients with hepatic impairment (including cholestatic cirrhosis), and in patients with renal impairment.

The clinical evidence base spans multiple Phase 2 and Phase 3 programs. The PRESS series of trials (PRESS I through PRESS VIII) established efficacy in diabetic dyslipidemia and hypertriglyceridemia, demonstrating non-inferiority to fenofibrate for triglyceride reduction and superiority to pioglitazone for lipid parameter improvement. The EVIDENCES series of trials evaluated saroglitazar in non-alcoholic fatty liver disease (NAFLD) and NASH, with the EVIDENCES II Phase 3 trial in India demonstrating significant histological improvement at 52 weeks. A US-based Phase 2 trial (Gawrieh et al. 2021) in 106 patients with biopsy-proven NASH demonstrated significant improvement in NAFLD activity score, liver enzymes, and lipid parameters at 16 weeks. In primary biliary cholangitis (PBC), the Phase 2 proof-of-concept study demonstrated a 49 to 51 percent reduction in alkaline phosphatase at 16 weeks in ursodeoxycholic acid-resistant or -intolerant patients, and the Phase IIb/III EPICS-III trial met its primary and secondary endpoints; regulatory submission to the United States Food and Drug Administration for this indication is anticipated in the first quarter of 2026. The compound has received orphan drug designation and Fast Track designation from the FDA for PBC.

Saroglitazar is well tolerated at the 4 mg clinical dose. The principal adverse events are mild gastrointestinal complaints (dyspepsia, gastritis), asthenia, and pyrexia, with no clinically significant effects on body weight, hepatic transaminases, renal function, creatine phosphokinase, or cardiac parameters at doses up to 128 mg in single-dose safety studies. The absence of the thiazolidinedione-class adverse events (peripheral edema, weight gain, bone fracture, bladder cancer signal) is attributed to the predominant PPARalpha and moderate PPARgamma pharmacological balance. This monograph reviews the chemistry, synthesis, and stereochemistry of saroglitazar; the dual-receptor pharmacology; the comprehensive human pharmacokinetic record; the clinical evidence base across diabetic dyslipidemia, NAFLD/NASH, PBC, and metabolic liver disease indications; reconstitution, sourcing, and handling considerations for laboratory work; stack-interaction implications; adverse-event and safety signals; and a comparative assessment of five alternative PPAR-targeting compounds against saroglitazar on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).